SELLAS Life Sciences elects Katherine Bach Kalin to its Board of Directors

SELLAS Life Sciences Group, Inc.

Elected on Aug 13, 2022 as Class II director, term until 2024 annual meeting.
Granted option for 19,000 shares at $3.10/share, vesting one year from grant.
Over 25 years life sciences experience; led corporate strategy at Celgene 2012-2017.
Also on boards of Genfit (GNFT), Brown Advisory, and FemHealth Ventures.
Board determined she is independent under SEC and Nasdaq rules.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Katherine Bach Kalin

Director

SLS · SELLAS Life Sciences Group, Inc.

Effective: 2022-08-13
Filed: August 16, 2022, 7:59 PM ET

On August 13, 2022, the Board of Directors (the “Board”) of SELLAS Life Sciences Group, Inc. (the “Company”) elected Katherine Bach Kalin as a member of the Board, effective immediately, to serve as a Class II director until the Company’s 2024 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Katherine Bach Kalin was elected as Director at SELLAS Life Sciences Group, Inc..

Action: elected
Role: Director

Exact text from the filing

On August 13, 2022, the Board of Directors (the “Board”) of SELLAS Life Sciences Group, Inc. (the “Company”) elected Katherine Bach Kalin as a member of the Board, effective immediately, to serve as a Class II director until the Company’s 2024 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal.

View on SEC.gov

SELLAS Life Sciences Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-091744

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.